Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
26 01 2021
26 01 2021
Historique:
received:
22
07
2020
accepted:
24
12
2020
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
20
8
2021
Statut:
epublish
Résumé
Extracellular vesicles (EVs) are relevant means for transferring signals across cells and facilitate propagation of oncogenic stimuli promoting disease evolution and metastatic spread in cancer patients. Here, we investigated the release of miR-424 in circulating small EVs or exosomes from prostate cancer patients and assessed the functional implications in multiple experimental models. We found higher frequency of circulating miR-424 positive EVs in patients with metastatic prostate cancer compared to patients with primary tumors and BPH. Release of miR-424 in small EVs was enhanced in cell lines (LNCaP
Identifiants
pubmed: 33500545
doi: 10.1038/s42003-020-01642-5
pii: 10.1038/s42003-020-01642-5
pmc: PMC7838273
doi:
Substances chimiques
MIRN424 microrna, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119Références
PLoS One. 2010 May 10;5(5):e10547
pubmed: 20479932
Eur Urol Oncol. 2019 Jul;2(4):415-424
pubmed: 31277777
Clin Chem. 2010 Nov;56(11):1733-41
pubmed: 20847327
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
Lancet. 2003 Mar 8;361(9360):859-64
pubmed: 12642065
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Nat Rev Urol. 2020 Jan;17(1):11-27
pubmed: 31827264
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Genes Dev. 2010 Sep 15;24(18):1967-2000
pubmed: 20844012
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Mol Cancer. 2019 Mar 30;18(1):52
pubmed: 30925917
Cancer Cell. 2016 Jun 13;29(6):846-858
pubmed: 27238081
Nat Med. 2013 Aug;19(8):1023-9
pubmed: 23817021
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Prostate. 2017 May;77(6):654-671
pubmed: 28156002
Oncogene. 2008 May 1;27(20):2877-85
pubmed: 18037958
Cancer Res. 2012 Jun 1;72(11):2889-900
pubmed: 22505649
Nat Cell Biol. 2011 Apr;13(4):423-33
pubmed: 21423178
Cancers (Basel). 2020 Jan 10;12(1):
pubmed: 31936761
Comput Struct Biotechnol J. 2016 Oct 27;15:8-13
pubmed: 27872688
Cancer Cell. 2016 Aug 8;30(2):243-256
pubmed: 27505671
Front Med (Lausanne). 2015 Jul 22;2:47
pubmed: 26258125
Br J Cancer. 1999 Sep;81(2):242-51
pubmed: 10496349
Front Immunol. 2018 Jun 13;9:1326
pubmed: 29951064
J Clin Invest. 2016 Dec 1;126(12):4585-4602
pubmed: 27820701
ACS Nano. 2020 Apr 28;14(4):4444-4455
pubmed: 32282185
J Extracell Vesicles. 2016 Feb 19;5:29975
pubmed: 26901056